<DOC>
	<DOC>NCT02183233</DOC>
	<brief_summary>The aim of this trial was to assess the efficacy and safety of Eschscholtzia Californica (EC) in treating patients having psycho-physiologic insomnia in a double-blind randomised placebo controlled trial during a 28-day treatment duration.</brief_summary>
	<brief_title>Efficacy and Safety of Eschscholtzia Californica in Treating Primary Insomnia</brief_title>
	<detailed_description />
	<mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
	<criteria>Male or female above 18 or below 65 years old Diagnosis of psychophysiologic insomnia, according to the criteria of DSMIV (Diagnostic and Statistical manual Version IV) Written informed consent Patient who is already taking other investigational drugs or who has taken part in another trial during the past three months Patient who has an history of psychiatric diseases, such as: anxiety disorders; the score of the HAMA (Hamilton anxiety scale) must be &lt; 10 depression according to the DSM IV criteria; the score of the HAMD (Hamilton depression scale) must be &lt; 10 mania schizophrenia dementia Patient who has an history of neurologic diseases, such as: Parkinson syndrome crania cerebral trauma post syndrome brain tumor fibromyalgia Patient who has an history of an iatrogenic insomnia, due to drugs like antidepressor, neuroleptic or benzodiazepine, hypnotic Patient with an hypersomnia or a sleep apnea syndrome Patient with any pathology inducing a chronic pain, a pyrosis, a nocturnal pollakiuria, a dyspnea Patient with a Restless Leg Syndrome Patient with severe hepatic or renal insufficiency which judged to be regarded as clinically relevant by the investigator, or any known clinically significant disease which may induce a risk for the patient in participating to the trial Breast feeding or pregnant female, or female with no efficient contraception method Patient with nonstabilised thyroid dysfunction Patient with a known allergy to Eschscholtzia Californica or its compounds Patient with alcohol or drug dependency Patient drinking tea, coffee or CocaCola after 4 p.m.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>